White Plains, NY, United States of America

Michael Van Meter

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Van Meter: Innovator in Antibody-Drug Conjugates

Introduction

Michael Van Meter is a notable inventor based in White Plains, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. His work focuses on innovative solutions for treating various disorders, showcasing his commitment to advancing medical science.

Latest Patents

Michael Van Meter holds a patent for "Anti-PTCRA antibody-drug conjugates and uses thereof." This patent provides a detailed disclosure of antibody-drug conjugates that comprise anti-PTCRA antibodies. The methods described in the patent are particularly useful for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and other disorders associated with elevated expression of PTCRA. He has 1 patent to his name, reflecting his innovative contributions to the field.

Career Highlights

Michael Van Meter is currently employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its focus on developing medicines for serious diseases. His role at Regeneron allows him to work at the forefront of medical research and development, contributing to groundbreaking therapies that can improve patient outcomes.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues such as Frank Kuhnert and Thomas Nittoli. These collaborations have fostered an environment of innovation and creativity, enabling the development of advanced therapeutic solutions.

Conclusion

Michael Van Meter's work in the field of antibody-drug conjugates exemplifies the impact of innovative thinking in biotechnology. His contributions are paving the way for new treatments that can significantly benefit patients suffering from serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…